Worth reading
0Immaterial
Scored from 1 of 3 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
4175
¥ million (expected proceeds)Wording
Conditional
How definitive the wording is.What was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-10-14
| Item | Details |
|---|
Items this document does not state (6)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correctionImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To raise in stages the funds needed before and around the start of Phase 3 clinical trials, accelerate the progress of the clinical trials, and avoid or limit dilution and erosion of shareholder value as far as possible.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.